Q2 FY27 revenue up 18.9%; FY29 target Rs 900-1,000 crore

Management guided margin improvementInvestor Communications View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹311.05

prior close

₹309.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+0.8% vs market

Pharmaceuticals peers, median of 170sector+0.6%+0.4% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.6

15m

-0.6

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+0.1+0.8+0.6+0.4

Next day

+0.3+0.7-0.4+1.1-0.8

-2.1-1.8-0.3-0.1-2.0

-1.7-0.4-1.3+0.2-1.9

-1.9-0.1-1.8+0.4-2.3

-0.9+2.1-3.0+1.5-2.4

+0.2pendingpending+2.2-2.0

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 18.9% year on year to Rs 175.9 crore and profit after tax rose 26.9% to Rs 14.1 crore. H1 revenue was Rs 341.5 crore, up 15.1%, and profit was Rs 27.8 crore, up 21.1%. Formulation revenue jumped 82% and export active ingredient revenue rose 28.5%. Management targets Rs 900-1,000 crore revenue and an 18-21% profit margin before interest, tax, depreciation and amortisation by FY29.

Likely market impact

Profit growth and better mix support the outlook, but active ingredient price pressure, capital spending and execution risks could temper gains.